Cells,
Journal Year:
2021,
Volume and Issue:
10(4), P. 730 - 730
Published: March 25, 2021
Cell
replacement
therapy
using
mesenchymal
(MSC)
and
other
stem
cells
has
been
evaluated
for
diabetic
retinopathy
glaucoma.
This
approach
significant
limitations,
including
few
integrated,
aberrant
growth,
surgical
complications.
Mesenchymal
Stem
Exosomes/Extracellular
Vesicles
(MSC
EVs),
which
include
exosomes
microvesicles,
are
an
emerging
alternative,
promoting
immunomodulation,
repair,
regeneration
by
mediating
MSC’s
paracrine
effects.
For
the
clinical
translation
of
EV
therapy,
it
is
important
to
determine
cellular
destination
time
course
uptake
in
retina
following
administration.
Here,
we
tested
fate
EVs
vivo
rat
retinas,
ex
retinal
explant,
primary
cells.
Intravitreally
administered
fluorescent
were
rapidly
cleared
from
vitreous.
Retinal
ganglion
(RGCs)
had
maximal
fluorescence
at
14
days
post
administration,
microglia
7
days.
Both
explant
model,
most
no
deeper
than
inner
nuclear
layer.
astrocytes,
microglia,
mixed
neurons
vitro
endocytosed
a
dose-dependent
manner.
Thus,
our
results
indicate
that
intravitreal
suited
treatment
diseases
affecting
retina.
Modification
surface
should
be
considered
maintaining
vitreous
prolonged
delivery.
Drug Delivery,
Journal Year:
2023,
Volume and Issue:
30(1)
Published: May 16, 2023
Ocular
posterior
segment
diseases
such
as
uveitis,
X-linked
juvenile
retinoschisis,
or
age-related
macular
degeneration
usually
result
in
progressive
and
irreversible
vision
loss.
Although
intravitreal
injection
is
the
main
way
to
deliver
drugs
eye,
it
still
has
shortcomings
an
invasive
operation.
Nanocontrolled
drug
delivery
technology
a
promising
option
avoid
frequent
injections.
Due
particularity
of
human
intraocular
structure,
have
unique
pharmacokinetic
characteristics
eye.
Various
nanoparticles
been
successfully
investigated
experimental
studies
for
vitreous
injection,
with
advantages
drawbacks.
Here,
we
introduce
ideal
nanopolymer
modifier
build
nanodelivery
systems
cavities.
Hyaluronic
acid
(HA)
natural
polysaccharide
broad
molecular
weight
range,
negatively
charged
surface,
ligand–receptor
binding
capabilities,
hyaluronidase
breakdown
capability.
Advances
CD44
receptor
targeting
HA-based
can
improve
mobility
penetration
retina,
stabilize
nanoparticles,
regulate
release.
This
review
summarizes
administration
nanoplatforms
based
on
HA
benefits
systems.
